Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is scheduled to be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same quarter in the previous year, the business earned ($0.54) EPS. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Stock Down 2.4 %

NASDAQ:IMUX opened at $1.21 on Friday. Immunic has a 52 week low of $0.95 and a 52 week high of $2.11. The stock’s 50-day moving average price is $1.50 and its 200-day moving average price is $1.35. The stock has a market capitalization of $109.00 million, a PE ratio of -0.81 and a beta of 1.84.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. B. Riley assumed coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 target price on shares of Immunic in a research note on Tuesday, July 16th. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research note on Monday, September 16th. Leerink Partners reiterated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $11.20.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.